[TEMPLATE – Intro TheraSphere to rest of hospital/community practices]

[physician practice letterhead]

Dear Physician-

The Interventional Radiology Department at [hospital name] offers an FDA-approved minimally invasive therapy to treat hepatocellular carcinoma (HCC). This therapy is TheraSphereTM Glass Microspheres which provides an excellent opportunity to expand upon the multidisciplinary options we can provide to patients, alongside surgery and systemic treatments. Below is some information about the technology for your consideration:

TheraSphere Y-90 Glass Microspheres is a selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status. TheraSphere does not disrupt current treatments.

Recent data released about TheraSphere showed that 100% of the patients enrolled in the LEGACY study showed a tumor response (complete response or partial response) up to 54 months post treatment. A 93% overall survival rate was achieved at 3 years in patients with transplant or resection following TheraSphere treatment.1 No patients experienced radiation liver-induced liver disease or failure, with a low rate (5.6%) of device/procedure rated serious adverse events (SAEs).

Please find additional information, a one-page overview of the LEGACY Study data for your review and more detail on the information above and consider recommending this proven therapy to treat HCC. When you see patients with HCC, we welcome your referral to our office for an IR consultation to discuss TheraSphere as a treatment option for your patients.

To schedule your patient for an IR office consultation please call [Name of patient coordinator] at [###-###-####].

Best regards,

[physician names within practice]

[Practice name]

[Phone]